NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis → Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad) Free GDTC Stock Alerts $2.13 -0.12 (-5.33%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$2.13▼$2.2450-Day Range$2.00▼$2.5052-Week Range$1.92▼$9.25Volume6,046 shsAverage Volume25,342 shsMarket Capitalization$23.30 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get CytoMed Therapeutics alerts: Email Address CytoMed Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside134.7% Upside$5.00 Price TargetShort InterestHealthy1.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector746th out of 929 stocksPharmaceutical Preparations Industry350th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingCytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytoMed Therapeutics has received no research coverage in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.08% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoMed Therapeutics has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDTC. Previous Next 2.5 News and Social Media Coverage News SentimentCytoMed Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CytoMed Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GDTC on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About CytoMed Therapeutics Stock (NASDAQ:GDTC)CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.Read More GDTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDTC Stock News HeadlinesMarch 27, 2024 | morningstar.comCytoMed Therapeutics Ltd GDTCMarch 20, 2024 | finance.yahoo.comCytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationMarch 18, 2024 | finanznachrichten.deCYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | markets.businessinsider.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | globenewswire.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 4, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairAugust 15, 2023 | finance.yahoo.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 8, 2023 | investing.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | finance.yahoo.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyJuly 11, 2023 | investorplace.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?See More Headlines Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GDTC CUSIPN/A CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+134.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio14.09 Quick Ratio14.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book2.73Miscellaneous Outstanding Shares10,940,000Free FloatN/AMarket Cap$23.30 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Chee Kong Choo (Age 66)Executive Chairman Comp: $27.32kDr. Wee Kiat Tan Ph.D. (Age 36)CEO, COO & Director Comp: $88.13kDr. Jieming Zeng M.D. (Age 50)Ph.D., Chief Scientific & Medical Officer and Director Comp: $89.74kMs. Yvonne Goh (Age 34)Chief Financial Officer Dr. Tien Wee Luk M.D. (Age 38)Chief Clinical Officer & Director Ms. Yoong Ying Tan (Age 35)Chief Corporate Officer More ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXBullfrog AINASDAQ:BFRGBenitec BiopharmaNASDAQ:BNTCTherapeuticsMDNASDAQ:TXMDAptorum GroupNASDAQ:APMView All Competitors GDTC Stock Analysis - Frequently Asked Questions Should I buy or sell CytoMed Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoMed Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GDTC shares. View GDTC analyst ratings or view top-rated stocks. What is CytoMed Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for CytoMed Therapeutics' shares. Their GDTC share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 134.7% from the stock's current price. View analysts price targets for GDTC or view top-rated stocks among Wall Street analysts. How have GDTC shares performed in 2024? CytoMed Therapeutics' stock was trading at $4.90 at the beginning of 2024. Since then, GDTC stock has decreased by 56.5% and is now trading at $2.13. View the best growth stocks for 2024 here. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering (IPO) on Friday, April 14th 2023. The company issued 2,412,369 shares at $4.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDTC) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe Exchange[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
